By Counterforce Health Team in Aldurazyme (laronidase) —

How to Get Aldurazyme (Laronidase) Covered by Blue Cross Blue Shield in North Carolina: Complete Appeals Guide with Forms and Deadlines

Answer Box: Getting Aldurazyme Covered by Blue Cross Blue Shield in North Carolina

Aldurazyme (laronidase) requires prior authorization from Blue Cross Blue Shield of North Carolina. Success depends on documented MPS I diagnosis via enzymatic testing and genetic confirmation. If denied, you have 120 days to file an external review through North Carolina's Smart NC program.

First steps today:

  1. Contact your specialist to gather MPS I diagnostic results (enzyme activity and IDUA gene testing)
  2. Request Blue Cross NC's prior authorization form through their provider portal
  3. Document any failed alternative treatments or contraindications

For denials: Call Smart NC at 1-855-408-1212 within 120 days of your final internal appeal denial.

Table of Contents

  1. Coverage at a Glance
  2. Step-by-Step: Fastest Path to Approval
  3. Common Denial Reasons & How to Fix Them
  4. Appeals Playbook for Blue Cross Blue Shield in North Carolina
  5. Clinician Corner: Medical Necessity Documentation
  6. Costs & Financial Assistance Options
  7. When to Escalate: Smart NC External Review
  8. FAQ: Common Questions

Coverage at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization Required before treatment Blue Cross NC Drug Search Blue Cross NC
Formulary Tier Specialty (Tier 5) - highest cost-sharing 2024 formulary documents Prime Therapeutics
Diagnosis Required Confirmed MPS I via enzyme/genetic testing FDA labeling requirements FDA Label
Appeals Deadline 120 days from final internal denial NC Department of Insurance Smart NC
Site of Care Infusion center or home health Blue Cross NC policies Infusion Guidelines

Step-by-Step: Fastest Path to Approval

1. Confirm Your MPS I Diagnosis Documentation

Who does it: Your metabolic specialist or geneticist
Documents needed: Enzymatic assay showing low/absent alpha-L-iduronidase activity and IDUA gene sequencing results
Timeline: Allow 2-3 weeks for genetic testing if not already completed
Source: MPS I Diagnostic Testing

2. Gather Treatment History

Who does it: You and your care team
Documents needed: Records of any prior MPS I treatments, failed therapies, or contraindications to alternatives
Timeline: 1-2 days to compile existing records

3. Request Prior Authorization Forms

Who does it: Your prescribing physician's office
How to submit: Through Blue Cross NC provider portal or by calling member services
Timeline: Forms typically available within 24-48 hours
Source: Blue Cross NC Provider Resources

4. Complete Medical Necessity Documentation

Who does it: Your specialist
Documents needed: Detailed clinical rationale, baseline assessments, monitoring plan
Timeline: 3-5 business days for thorough documentation

5. Submit Prior Authorization Request

Who does it: Your physician's office
How to submit: Provider portal, fax, or mail (verify current submission method)
Timeline: Blue Cross NC typically responds within 5-15 business days

6. Monitor for Decision

Who does it: You and your care team
Expected timeline: Standard PA decisions within 15 days; expedited within 72 hours for urgent cases

7. Appeal if Denied

Who does it: You with physician support
Timeline: Must file within plan's internal appeal deadline (typically 60-180 days)
Next step: Smart NC external review if internal appeals fail

Common Denial Reasons & How to Fix Them

Denial Reason How to Overturn Required Documents
"Diagnosis not confirmed" Submit enzymatic and genetic testing results Lab reports showing low IDUA activity + IDUA gene variants
"Not medically necessary" Provide clinical evidence of MPS I severity Baseline organ function tests, imaging, specialist assessment
"Alternative treatments available" Document contraindications or failures Medical records showing HSCT ineligibility or prior treatment failures
"Quantity limits exceeded" Weight-based dosing justification Current weight, BSA calculations, FDA dosing guidelines
"Site of care not approved" Infusion center requirements Documentation of infusion reaction monitoring capabilities

Key Documentation Tips:

  • Include both enzymatic (low alpha-L-iduronidase) and genetic (IDUA mutations) confirmation
  • Reference FDA labeling for dosing and administration requirements
  • Provide baseline assessments of organ involvement (cardiac, respiratory, skeletal)

Appeals Playbook for Blue Cross Blue Shield in North Carolina

Internal Appeals Process

Level 1 Internal Appeal

  • Deadline: 60 days from denial notice (verify with your specific plan)
  • How to file: Written request to Blue Cross NC appeals department
  • Timeline: Decision within 30 days (15 days for urgent cases)
  • Required: Original denial letter, medical records, physician letter of support

Level 2 Internal Appeal (if offered)

  • Deadline: 60 days from Level 1 denial
  • Process: Independent medical review within Blue Cross NC
  • Timeline: 30 days for standard, 72 hours for urgent

External Review Through Smart NC

When to Use: After exhausting internal appeals or for urgent cases

  • Deadline: 120 days from final internal denial
  • Contact: Smart NC at 1-855-408-1212
  • Cost: Free to patients
  • Timeline: 45 days standard, 72 hours expedited
  • Binding: Yes - Blue Cross NC must comply with favorable decisions

How to File:

  1. Download external review form from NC Department of Insurance
  2. Include all denial letters and medical documentation
  3. Submit within 120-day deadline
  4. Smart NC assigns independent medical reviewer

Success Factors:

  • Comprehensive medical documentation
  • Clear demonstration of medical necessity
  • Evidence that treatment meets FDA-approved indications
  • Documentation of failed alternatives or contraindications

Clinician Corner: Medical Necessity Documentation

Essential Components for Aldurazyme Prior Authorization

Diagnosis Confirmation:

  • Enzymatic assay results showing deficient alpha-L-iduronidase activity
  • Molecular genetic testing confirming IDUA gene mutations
  • Elevated urinary glycosaminoglycans (supporting evidence)
  • Clinical phenotype classification (Hurler, Hurler-Scheie, or Scheie syndrome)

Clinical Assessment:

  • Baseline organ system involvement (cardiac, pulmonary, hepatic, skeletal, CNS)
  • Functional status assessments
  • Growth parameters and developmental milestones
  • Photographic documentation of physical features (if applicable)

Treatment Rationale:

  • Weight-based dosing calculations (0.58 mg/kg weekly)
  • Infusion monitoring protocol and safety measures
  • Expected clinical outcomes and monitoring plan
  • Contraindications to hematopoietic stem cell transplantation (if applicable)

Supporting Literature:

  • Reference FDA-approved labeling for MPS I treatment
  • Cite relevant clinical practice guidelines
  • Include peer-reviewed efficacy data when available
Tip: Include a detailed monitoring plan showing how you'll assess treatment response through pulmonary function tests, echocardiograms, liver/spleen measurements, and functional assessments. This demonstrates ongoing medical oversight and justifies continued therapy.

Costs & Financial Assistance Options

Manufacturer Support Programs

Sanofi Patient Assistance:

  • Copay assistance for eligible commercially insured patients
  • Patient support services for treatment coordination
  • Contact: Visit Aldurazyme.com for current programs

Foundation Grants

  • National Organization for Rare Disorders (NORD)
  • Patient Advocate Foundation
  • HealthWell Foundation (check current rare disease programs)

State Programs

  • North Carolina Medicaid (for eligible patients)
  • State pharmaceutical assistance programs (verify current availability)

Cost Context: Aldurazyme wholesale acquisition cost is approximately $1,113.38 per 2.9 mg vial (as of January 2025), with treatment requiring multiple vials per infusion based on patient weight.

When to Escalate: Smart NC External Review

The Smart NC program provides North Carolina residents with powerful appeal rights that can overturn Blue Cross Blue Shield denials.

Contact Smart NC When:

  • Internal appeals have been exhausted or denied
  • Treatment delay could seriously harm your health
  • You need help navigating the appeals process

Smart NC Advantages:

  • Free independent medical review
  • Experienced staff assistance with forms and documentation
  • Binding decisions that insurers must follow
  • Expedited process for urgent cases (72-hour decisions)

Success Stories Pattern: While specific Aldurazyme cases aren't publicly documented, Smart NC has successfully overturned denials for other high-cost specialty medications when patients provided comprehensive medical documentation and demonstrated clear medical necessity.

How Counterforce Health Can Help: Counterforce Health specializes in turning insurance denials into successful appeals by analyzing denial letters, identifying specific coverage criteria, and crafting evidence-backed rebuttals. Their platform helps patients and clinicians navigate complex prior authorization requirements and appeal processes for specialty medications like Aldurazyme.

Contact Information:

FAQ: Common Questions

Q: How long does Blue Cross Blue Shield prior authorization take for Aldurazyme in North Carolina? A: Standard prior authorizations typically take 5-15 business days. Expedited reviews for urgent cases must be completed within 72 hours under North Carolina law.

Q: What if Aldurazyme is not on my Blue Cross NC formulary? A: You can request a formulary exception by demonstrating medical necessity and providing documentation that alternative treatments are inappropriate or have failed.

Q: Can I request an expedited appeal if my treatment is delayed? A: Yes. If delay could seriously jeopardize your health or ability to regain function, you can request expedited internal appeals (72 hours) and expedited external review through Smart NC.

Q: What happens if I move from another state where I was already receiving Aldurazyme? A: Document your treatment history and clinical response. Blue Cross NC should consider prior authorization more favorably when there's evidence of established medical necessity and treatment benefit.

Q: Do I need to try other treatments first (step therapy)? A: For MPS I, there are no therapeutic alternatives to enzyme replacement therapy with Aldurazyme. Hematopoietic stem cell transplant is a different treatment approach with specific eligibility criteria.

Q: How often do I need to renew prior authorization? A: Most plans require annual reauthorization with updated clinical documentation showing continued medical necessity and treatment benefit.

Q: What if my infusion center isn't in Blue Cross NC's network? A: You may request an out-of-network exception if no in-network providers can safely administer Aldurazyme with appropriate monitoring capabilities.

Q: Can Smart NC help with the initial prior authorization, or only appeals? A: Smart NC primarily handles external reviews after internal appeals. For initial prior authorization assistance, contact Blue Cross NC member services or work with your healthcare provider.

Sources & Further Reading

Disclaimer: This guide provides general information about insurance coverage processes and should not be considered medical or legal advice. Insurance policies, coverage criteria, and appeal procedures can change. Always verify current requirements with Blue Cross Blue Shield of North Carolina and consult with your healthcare providers for medical decisions. For personalized assistance with appeals and prior authorization, Counterforce Health offers specialized support in navigating insurance coverage challenges for specialty medications.

From our advocates: "We've seen the biggest difference in approval rates when families work closely with their MPS specialist to document not just the diagnosis, but the specific clinical features and progression that make enzyme replacement therapy essential. The key is showing Blue Cross NC exactly how the patient meets their coverage criteria with concrete medical evidence, not just a general MPS I diagnosis. This approach has helped several families avoid lengthy appeals processes."

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.